The obesity epidemic: Current and future pharmacological treatments

被引:67
作者
Hofbauer, Karl G. [1 ]
Nicholson, Janet R.
Boss, Olivier
机构
[1] Univ Basel, Biozentrum Pharmazentrum, CH-4056 Basel, Switzerland
[2] Sirtris Pharmaceut Inc, Cambridge, MA 02139 USA
关键词
appetite; satiety; energy balance; adipose tissue; drugs;
D O I
10.1146/annurev.pharmtox.47.120505.105256
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The unabated rise in the prevalence of obesity is a challenge for global health care systems. Efforts to reverse this trend by dietary or behavioral counseling have not been successful, which has stimulated efforts to find a role for pharmacotherapy. Currently only a small number of antiobesity drugs are approved for long-term use and only a few compounds are in clinical development. Despite recent progress in the understanding of the regulation of energy balance, drug discovery has been less productive than expected. In the present review, the clinically available antiobesity agents are discussed. Examples of drug candidates that are currently in development are given and the possible future range of antiobesity agents is illustrated by the targets being addressed in drug discovery. Finally, the efficacy of antiobesity agents and their value in the treatment of obesity are assessed in comparison with other therapeutic approaches, such as surgery and changes in lifestyle.
引用
收藏
页码:565 / 592
页数:28
相关论文
共 131 条
[1]   Leptin signaling [J].
Ahima, RS ;
Osei, SY .
PHYSIOLOGY & BEHAVIOR, 2004, 81 (02) :223-241
[2]   Resistin: yet another adipokine tells us that men are not mice [J].
Arner, P .
DIABETOLOGIA, 2005, 48 (11) :2203-2205
[3]   The efficacy and safety of sibutramine for weight loss - A systematic review [J].
Arterburn, DE ;
Crane, PK ;
Veenstra, DL .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (09) :994-1003
[4]   Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes - A systematic review [J].
Aucott, L ;
Poobalan, A ;
Smith, WCS ;
Avenell, A ;
Jung, R ;
Broom, J .
HYPERTENSION, 2005, 45 (06) :1035-1041
[5]   The gut and energy balance: Visceral allies in the obesity wars [J].
Badman, MK ;
Flier, JS .
SCIENCE, 2005, 307 (5717) :1909-1914
[6]   Divergence of melanocortin pathways in the control of food intake and energy expenditure [J].
Balthasar, N ;
Dalgaard, LT ;
Lee, CE ;
Yu, J ;
Funahashi, H ;
Williams, T ;
Ferreira, M ;
Tang, V ;
McGovern, RA ;
Kenny, CD ;
Christiansen, LM ;
Edelstein, E ;
Choi, B ;
Boss, O ;
Aschkenasi, C ;
Zhang, CY ;
Mountjoy, K ;
Kishi, T ;
Elmquist, JK ;
Lowell, BB .
CELL, 2005, 123 (03) :493-505
[7]   Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension [J].
Bátkai, S ;
Pacher, P ;
Osei-Hyiaman, D ;
Radaeva, S ;
Liu, J ;
Harvey-White, J ;
Offertáler, L ;
Mackie, K ;
Rudd, MA ;
Bukoski, RD ;
Kunos, G .
CIRCULATION, 2004, 110 (14) :1996-2002
[8]   Inhibition of food intake in obese subjects by peptide YY3-36 [J].
Batterham, RL ;
Cohen, MA ;
Ellis, SM ;
Le Roux, CW ;
Withers, DJ ;
Frost, GS ;
Ghatei, MA ;
Bloom, SR .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (10) :941-948
[9]   Current and investigational antiobesity agents and obesity therapeutic treatment targets [J].
Bays, HE .
OBESITY RESEARCH, 2004, 12 (08) :1197-1211
[10]   Obesity and physical activity: A review [J].
Bensimhon, DR ;
Kraus, WE ;
Donahue, MP .
AMERICAN HEART JOURNAL, 2006, 151 (03) :598-603